Assignee
IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC
CN·5 granted patents·3 pending applications·11 citations·filing 2021–2024
Top patents by PatentIndex Score
8 records- 0192US11672859B2Recombinant fusion proteins targeting CD47 and PD-L1, preparation and use thereofIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC·Filed 2021·Granted Jun 13, 2023·3 cites·15 claims
- 0290US11613584B1Antibodies binding CD70, preparation and use thereofIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC·Filed 2022·Granted Mar 28, 2023·8 cites·16 claims
- 0379US2025127855A1Combination Therapy for CMML and MDSIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC·Filed 2023·Application pending·0 cites
- 0471US12528866B2Recombinant protein targeting PD-L1 and VEGF and compositions thereofIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC·Filed 2022·Granted Jan 20, 2026·0 cites·6 claims
- 0564US2025332216A1Combination therapy for classic hodkin's lymphomaIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC·Filed 2024·Application pending·0 cites
- 0659US2023167194A1Recombinant bifunctional protein targeting cd47 and her2IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC·Filed 2022·Application pending·0 cites
- 0755US11926675B2Antibodies binding CD24, preparation and use thereofIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC·Filed 2022·Granted Mar 12, 2024·0 cites·14 claims
- 0855US11891449B2Recombinant fusion proteins targeting CD47 and CD24, preparation and use thereofIMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC·Filed 2021·Granted Feb 6, 2024·0 cites·18 claims
Join the waitlist — get patent alerts
Get an alert when IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →